SGLT2 inhibitors produce a transient, dose-dependent reduction in eGFR [59, 112], which is reversible on stopping treatment [136]; additionally, real-world data show that SGLT2 inhibitors are not associated with an increased risk of AKI [137, 138]. Here, SLC5A2 is linked to acute kidney injury.